Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Levocarnitine in Anemia, Sickle Cell: NCT05081349 Clinical Landscape Report 2026
16 October 2026
NCT05081349 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Famotidine in Anemia, Sickle Cell: NCT05084521 Clinical Landscape Report 2026
16 October 2026
NCT05084521 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Guanabenz Acetate in Metabolic Dysfunction Associated Steatohepatitis: NCT05084404 Clinical Landscape Report 2026
16 October 2026
NCT05084404 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Norursodeoxycholic acid in Metabolic Dysfunction Associated Steatohepatitis: NCT05083390 Clinical Landscape Report 2026
16 October 2026
NCT05083390 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Recombinant Human Coagulation Factor VIII (Takeda) in Hemophilia A: CTRI/2021/10/037406 Clinical Landscape Report 2026
16 October 2026
CTRI/2021/10/037406 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ALG-055009 in Metabolic Dysfunction Associated Steatohepatitis: NCT05090111 Clinical Landscape Report 2026
16 October 2026
NCT05090111 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Tideglusib in Amyotrophic Lateral Sclerosis: NCT05105958 Clinical Landscape Report 2026
16 October 2026
NCT05105958 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rifaximin in Hemoglobin SC Disease: NCT05098028 Clinical Landscape Report 2026
16 October 2026
NCT05098028 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rentosertib in Idiopathic Pulmonary Fibrosis: ACTRN12621001541897 Clinical Landscape Report 2026
16 October 2026
ACTRN12621001541897 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Miricorilant in Metabolic Dysfunction Associated Steatohepatitis: NCT05117489 Clinical Landscape Report 2026
16 October 2026
NCT05117489 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
ASC-41 in Metabolic Dysfunction Associated Steatohepatitis: NCT05118360 Clinical Landscape Report 2026
16 October 2026
NCT05118360 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Tolebrutinib in Myasthenia Gravis: NCT05132569 Clinical Landscape Report 2026
16 October 2026
NCT05132569 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.